Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

65.0K
Overview
65.0K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

3.7K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
3.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.1K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

14.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
14.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TTC7A deficiency: A retrospective international study on treatment and outcomes from the Inborn Errors Working Party of EBMT.

Journal of human immunity·2026
Same author

The IL-10/IL-6 Ratio and the Risk Score: Two Cytokines-Based Predictors for Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adults (M-HLHa).

American journal of hematology·2026
Same author

Intronic branchpoint-to-acceptor variants underlying inborn errors of immunity.

Journal of human immunity·2025
Same author

Kinesin-1 coordinates cross-talk between microtubule and actin cytoskeletons during dendritic cell migration.

Science advances·2025
Same author

LRO biogenesis and function: what can we learn from mast cells?

Frontiers in cell and developmental biology·2025
Same author

Beyond genotype: challenges in predicting disease risk for carriers of biallelic perforin variants.

Blood·2025

Related Experiment Video

Updated: May 7, 2026

Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells
09:49

Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells

Published on: November 10, 2010

19.2K

EBAG9 tempers lymphocyte killing activity.

Gaël Ménasché1, Geneviève de Saint Basile

  • 1INSERM U768, Paris, France.

The Journal of Clinical Investigation
|July 22, 2009
PubMed
Summary

The absence of EBAG9 protein enhances cytotoxic T lymphocyte (CTL) activity by affecting how they traffic cellular weapons. This discovery offers a new target for modulating CTL responses in immune regulation.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Medicine

Background:

  • Lymphocyte cytotoxic activity is vital for immune surveillance and maintaining bodily balance.
  • Genetic defects in granule trafficking or exocytosis have illuminated the molecular regulation of cytotoxicity.
  • Cytotoxic T lymphocytes (CTLs) and Natural Killer (NK) cells are key players in cell-mediated immunity.

Discussion:

  • Rüder and colleagues demonstrate that engineered absence of EBAG9 enhances CTL cytotoxic activity.
  • This effect was not observed in NK cells, suggesting cell-type-specific mechanisms.
  • EBAG9 may regulate the endosomal-lysosomal trafficking of cytotoxic effectors within CTLs.

Key Insights:

  • Engineered absence of EBAG9 significantly boosts CTL cytotoxic function.

More Related Videos

Isolation of Murine Lymph Node Stromal Cells
05:47

Isolation of Murine Lymph Node Stromal Cells

Published on: August 19, 2014

31.2K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.3K

Related Experiment Videos

Last Updated: May 7, 2026

Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells
09:49

Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells

Published on: November 10, 2010

19.2K
Isolation of Murine Lymph Node Stromal Cells
05:47

Isolation of Murine Lymph Node Stromal Cells

Published on: August 19, 2014

31.2K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.3K
  • EBAG9's role appears specific to CTLs, not NK cells.
  • The protein likely influences the trafficking pathways for cytotoxic molecules in CTLs.

    • Outlook:

    • This research identifies EBAG9 as a potential target for modulating CTL responsiveness.
    • Understanding EBAG9's role could lead to new therapeutic strategies for immune-related diseases.
    • Further investigation into EBAG9's precise trafficking mechanisms is warranted.